Shingrix is a recombinant zoster vaccine designed to prevent shingles and related complications in adults. It is recommended for immunocompetent adults aged 50 years and older, as well as for those aged 19 years and older who are or will be immunocompromised due to disease or therapy.
Clinical data show strong efficacy against herpes zoster across diverse populations, with protection sustained for multiple years. Understanding dosing schedules, safety signals, and practical administration guidance helps clinicians and patients make informed decisions about timing and adherence.
| Vaccine | Type | Primary Series | Key Target Population |
|---|---|---|---|
| Shingrix | Recombinant protein (AS01 adjuvant) | 2 doses, 2–6 months apart | Adults ≥50 years; immunocompromised adults ≥19 years |
| Zostavax | Live attenuated zoster vaccine | 1 single dose | Historically adults ≥60 years; now largely replaced by Shingrix |
| Other vaccines (e.g., non-recombinant candidates) | Varies | Varies | Not routinely recommended over Shingrix in most guidelines |
Eligibility Criteria And Age Guidance
Recommended Age Groups And Health Status
Current guidelines prioritize Shingrix for adults aged 50 years and older regardless of prior shingles or zoster vaccination history. Adults aged 19 years and older who are or will be immunocompromised due to disease or therapy should also receive the vaccine, reflecting the increased risk of severe zoster in these populations.
Schedule And Dosing Considerations
Two-dose Series And Timing Flexibility
Shingrix requires two doses for optimal protection. The interval between doses is typically 2 to 6 months, with 6 months preferred when feasible. Research supports flexibility in extending the second dose beyond 6 months if needed, while earlier administration is not routinely recommended.
Safety And Common Side Effects
Local And Systemic Reactions
The most common side effects are localized and temporary, including pain, erythema, and swelling at the injection site. Systemic reactions such as fatigue, headache, shivering, fever, and gastrointestinal symptoms may occur, particularly after the first dose and are generally mild to moderate in severity.
Efficacy And Real-world Performance
Protection Against Shingles And Complications
Post-licensure studies continue to demonstrate high vaccine effectiveness against herpes zoster and related complications, including postherpetic neuralgia. Effectiveness remains robust across a wide range of ages and in individuals with controlled chronic conditions, reinforcing confidence in routine use.
Key Takeaways And Practical Guidance
- Shingrix is recommended for adults aged 50 years and older and for immunocompromised adults aged 19 years and older.
- It requires a two-dose series, ideally spaced 2 to 6 months apart for optimal durability of protection.
- Common side effects are mostly local and temporary, with systemic reactions typically mild to moderate in intensity.
- Vaccination is advised even after a prior episode of shingles or prior zoster vaccination with Zostavax.
- Real-world effectiveness against zoster and complications remains high across diverse patient groups and age ranges.
FAQ
Reader questions
Can Shingrix be given if I have already had shingles?
Yes. A history of shingles is not a contraindication to vaccination. The immune response triggered by natural infection does not reliably protect against future episodes, and vaccination is recommended once the acute rash has resolved.
Is it safe to receive Shingrix if I am immunocompromised?
Yes. Shingrix is a non-live recombinant vaccine and is recommended for immunocompromised adults aged 19 years and older. These individuals are at higher risk for zoster and severe disease, making vaccination an important part of their care plan.
What should I do if I miss the recommended interval between doses?
There is no need to restart the series if the second dose is delayed. Administer the missing dose as soon as practicable, and continue with the schedule using the original product for all doses. The protective benefit remains strong regardless of slight variations in timing.
How does Shingrix compare with the older shingles vaccine?
Unlike the older live attenuated vaccine, Shingrix is a recombinant product with a non-live, adjuvanted formulation. It provides higher and more sustained efficacy across all age groups and is now the preferred choice in current guidelines, replacing Zostavax in most clinical practice.